- Previous Close
189.45 - Open
191.62 - Bid 201.72 x 900
- Ask 201.39 x 800
- Day's Range
188.54 - 202.35 - 52 Week Range
135.85 - 202.35 - Volume
8,263,245 - Avg. Volume
4,651,546 - Market Cap (intraday)
355.917B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
67.39 - EPS (TTM)
2.99 - Earnings Date Oct 30, 2024
- Forward Dividend & Yield 6.20 (3.27%)
- Ex-Dividend Date Oct 15, 2024
- 1y Target Est
203.67
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
www.abbvie.com50,000
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - General
Industry
Recent News: ABBV
View MorePerformance Overview: ABBV
Trailing total returns as of 2024-10-30, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABBV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABBV
View MoreValuation Measures
Market Cap
334.63B
Enterprise Value
392.11B
Trailing P/E
63.36
Forward P/E
15.80
PEG Ratio (5yr expected)
0.45
Price/Sales (ttm)
6.11
Price/Book (mrq)
49.37
Enterprise Value/Revenue
7.13
Enterprise Value/EBITDA
21.68
Financial Highlights
Profitability and Income Statement
Profit Margin
9.71%
Return on Assets (ttm)
7.94%
Return on Equity (ttm)
54.26%
Revenue (ttm)
55B
Net Income Avi to Common (ttm)
5.3B
Diluted EPS (ttm)
2.99
Balance Sheet and Cash Flow
Total Cash (mrq)
13.16B
Total Debt/Equity (mrq)
1,039.99%
Levered Free Cash Flow (ttm)
19.64B